Lloyd P Haskell (Lloyd Haskell)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 13

Top Topics

Peripheral Artery Disease

Top Venues

Journal of the American Heart Association

Journal of thrombosis and haemostasis : JTH

This page only lists publications with an associated author ORCID identifier.

Publications

Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association (2024)
Shea E Hogan, Eike Sebastian Debus, Mark R Nehler, Manesh R Patel, Sonia S Anand, Eva Muehlhofer, Lloyd P Haskell, Scott D Berkowitz, Rupert M Bauersachs, Marc P Bonaca
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD. Circulation 149 (8) (2024)
Shea E Hogan, Eike Sebastian Debus, Mark R Nehler, Manesh R Patel, Sonia S Anand, Eva Muehlhofer, Lloyd P Haskell, Scott D Berkowitz, Rupert M Bauersachs, Marc P Bonaca
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD. Circulation 149 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Justin T Morrison, Mario Enrico Canonico, Sonia S Anand, Manesh R Patel, Eike Sebastian Debus, Mark R Nehler, Connie N Hess, Judith Hsia, Warren H Capell, Eva Muehlhofer, Lloyd P Haskell, Scott D Berkowitz, Rupert M Bauersachs, Marc P Bonaca
Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD. Circulation 149 (19) (2024)
Shea E Hogan, Eike Sebastian Debus, Mark R Nehler, Manesh R Patel, Sonia S Anand, Eva Muehlhofer, Lloyd P Haskell, Scott D Berkowitz, Rupert M Bauersachs, Marc P Bonaca
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD. Circulation 149 (8) (2024)
Shea E Hogan, Eike Sebastian Debus, Mark R Nehler, Manesh R Patel, Sonia S Anand, Eva Muehlhofer, Lloyd P Haskell, Scott D Berkowitz, Rupert M Bauersachs, Marc P Bonaca
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD. Circulation 149 (8) (2024)
Jennifer A Rymer, Sonia S Anand, Eike Sebastian Debus, Lloyd P Haskell, Connie N Hess, W Schuyler Jones, Eva Muehlhofer, Scott D Berkowitz, Rupert M Bauersachs, Marc P Bonaca, Manesh R Patel
Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD. Circulation (2023)
Scott D Berkowitz, Rupert M Bauersachs, Michael Szarek, Mark R Nehler, Eike Sebastian Debus, Manesh R Patel, Sonia S Anand, Warren H Capell, Connie N Hess, Judith Hsia, Nicholas J Leeper, David De Padua Brasil, Lajos Mátyás, Rafael Diaz, Marianne Brodmann, Eva Muehlhofer, Lloyd P Haskell, Marc P Bonaca
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. Journal of thrombosis and haemostasis : JTH 20 (5) (2022)